Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV 10% in Autoimmune Encephalitis
NCT04175522Phase 2Completed
- Sponsor
- GC Biopharma
- Start
- Nov 2019
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of intravenous immunoglobulin G in Autoimmune Encephalitis (AE), sponsored by GC Biopharma. Primary endpoint: Modified Rankin Scale at 28 days. Started Nov 2019; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT04175522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175522.